GlassScriptPhysician profile
Abigail M Cay
NPI 1982816229
$10,978.00
in general payments reported to CMS, 2019-2025
51 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $504 · 2021: $1,407 · 2022: $1,885 · 2023: $2,088 · 2024: $2,084 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,887.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,075.92 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,229.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $976.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $847.97 | 2021-2025 | |
| Lilly USA, LLC | $548.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $530.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.73 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $394.60 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $368.39 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $325.89 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.96 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $260.16 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $251.22 | 2020-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $195.10 | 2022 | |
| Lundbeck LLC | $193.90 | 2022-2025 | Vyepti, Rexulti |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Cay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.